Ali AlMail
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali AlMail has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Gregory Costain
The Hospital for Sick Children
3 shared publications Adam Shlien
Program in Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada; Division of Genome Diagnostics, Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
2 shared publicationsBhooma Thiruvahindrapuram
The Centre for Applied Genomics, SickKids Research Institute, Toronto, ON, Canada
2 shared publications- Bushra Haque
The Hospital for Sick Children
2 shared publications Christian R. Marshall
Division of Genome Diagnostics, Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
2 shared publications- David Cheerie
Hospital for Sick Children
2 shared publications
Latest Publications
- Open Access
- 23 April 2024
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 5 (3) , 100299
A systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods
- 23 April 2024
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 5 (3) , 100299
Open AccessA systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods
- Open Access
Gaps in the phenotype descriptions of ultra-rare genetic conditions: review and multicenter consensus reporting guidelines
Background: Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. Methods: We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. Results: In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and behavioural issues, or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain. Conclusion: Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.
Open AccessGaps in the phenotype descriptions of ultra-rare genetic conditions: review and multicenter consensus reporting guidelines
Background: Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear. Methods: We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries. Results: In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and behavioural issues, or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain. Conclusion: Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.
- Open Access
A systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods
Background/Objectives: Canonical splice site variants (CSSVs) are often presumed to cause loss-of-function (LoF) and are assigned very strong evidence of pathogenicity (according to ACMG criterion PVS1). However, the exact nature and predictability of splicing effects of unselected rare CSSVs in blood-expressed genes is poorly understood. Methods: A total of 184 rare CSSVs in unselected blood-expressed genes were identified by genome sequencing in 121 individuals, and their impact on splicing was interrogated manually in RNA sequencing (RNA-seq) data. Blind to these RNA-seq data, we attempted to predict the precise impact of CSSVs by applying in silico tools and the ClinGen Sequence Variant Interpretation Working Group 2018 guidelines for applying PVS1 criterion. Results: There was no evidence of a frameshift nor of reduced expression consistent with nonsense-mediated decay (NMD) for 24% of CSSVs: 17% had wildtype splicing only and normal junction depths, 3.25% resulted in cryptic splice site usage and in-frame indels, 3.25% resulted in full exon skipping (in-frame), and 0.5% resulted in full intron inclusion (in-frame). Misclassification rates for splicing outcome (frameshift/NMD vs. no frameshift/no NMD) using (i) SpliceAI, (ii) MaxEntScan, and (iii) AutoPVS1 ranged from 30-41%, with none outperforming a simple “zero rule” classifier. Conclusion: Nearly 1 in 4 CSSVs may not cause LoF based on analysis of RNA-seq data. Predictions from in silico methods were often discordant with findings from RNA-seq. More caution may be warranted in applying PVS1-level evidence to CSSVs in the absence of functional data.
Open AccessA systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods
Background/Objectives: Canonical splice site variants (CSSVs) are often presumed to cause loss-of-function (LoF) and are assigned very strong evidence of pathogenicity (according to ACMG criterion PVS1). However, the exact nature and predictability of splicing effects of unselected rare CSSVs in blood-expressed genes is poorly understood. Methods: A total of 184 rare CSSVs in unselected blood-expressed genes were identified by genome sequencing in 121 individuals, and their impact on splicing was interrogated manually in RNA sequencing (RNA-seq) data. Blind to these RNA-seq data, we attempted to predict the precise impact of CSSVs by applying in silico tools and the ClinGen Sequence Variant Interpretation Working Group 2018 guidelines for applying PVS1 criterion. Results: There was no evidence of a frameshift nor of reduced expression consistent with nonsense-mediated decay (NMD) for 24% of CSSVs: 17% had wildtype splicing only and normal junction depths, 3.25% resulted in cryptic splice site usage and in-frame indels, 3.25% resulted in full exon skipping (in-frame), and 0.5% resulted in full intron inclusion (in-frame). Misclassification rates for splicing outcome (frameshift/NMD vs. no frameshift/no NMD) using (i) SpliceAI, (ii) MaxEntScan, and (iii) AutoPVS1 ranged from 30-41%, with none outperforming a simple “zero rule” classifier. Conclusion: Nearly 1 in 4 CSSVs may not cause LoF based on analysis of RNA-seq data. Predictions from in silico methods were often discordant with findings from RNA-seq. More caution may be warranted in applying PVS1-level evidence to CSSVs in the absence of functional data.